What is CUSIP 31572Q808?

CUSIP 31572Q808 is the security identifier used in SEC filing datasets for FGEN - KYNTRA BIO, INC. - Common Stock, $0.01 par value.

Who owns FGEN - KYNTRA BIO, INC. - Common Stock, $0.01 par value based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

Security Snapshot

KYNTRA BIO, INC. - Common Stock, $0.01 par value (FGEN) Institutional Ownership

CUSIP: 31572Q808

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.31

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, $0.01 par value
Symbol: FGEN on Nasdaq
Shares outstanding: 4,048,583
SEC-reported price per share: $0.31

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

FGEN - KYNTRA BIO, INC. - Common Stock, $0.01 par value is tracked under CUSIP 31572Q808.
Latest finished 13F holder period is not available.
2 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 1 to 0 between Q2 2025 and Q3 2025.
SEC-reported value moved from $79,500 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

31572Q808

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

FGEN full holder history KYNTRA BIO, INC. SEC filings KYNTRA BIO, INC. company facts KYNTRA BIO, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 31572Q808:

Q3 2025 (0 holders) Q2 2025 (1 holder) Q1 2025 (52 holders) Q4 2024 (65 holders) Q3 2024 (68 holders) Q2 2024 (100 holders) Q1 2024 (106 holders) Q4 2023 (99 holders) Q3 2023 (106 holders) Q2 2023 (149 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

FGEN

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
PRIMECAP MANAGEMENT CO/CA/	4.6%		$1,523,323		4,616,130		PRIMECAP MANAGEMENT CO/CA/	31 Dec 2024
ARMISTICE CAPITAL, LLC	9.9%	+18%	$124,000	-$2,511,000	400,000	-95%	Armistice Capital, LLC	31 Mar 2026

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

n/a

Rows shown

1-25 of 44

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q3	0	$0	-$79,500			$0.31	0
2025 Q2	15,000	$79,500	-$10,137,427	$0	$0	$5.30	1
2025 Q1	32,974,661	$10,217,322	-$1,814,128	$31,741	$131,917	$0.31	52
2024 Q4	36,261,009	$19,199,469	-$4,577,110	$55,842	$167,345	$0.53	65
2024 Q3	45,933,468	$18,857,141	-$6,430,829	$268,384	$140,567	$0.40	68
2024 Q2	56,537,431	$50,439,989	-$9,081,706	$807,837	$1,881,657	$0.89	100
2024 Q1	61,231,274	$143,890,300	-$18,865,510	$518,880	$3,536,515	$2.35	106
2023 Q4	70,070,394	$62,097,852	+$1,475,033	$58,053	$1,671,266	$0.89	99
2023 Q3	68,326,642	$58,948,042	-$26,264,926	$54,190	$1,667,977	$0.86	106
2023 Q2	76,278,245	$205,953,752	-$161,076,321	$10,365,770	$20,623,520	$2.70	149
2023 Q1	76,360,130	$1,424,871,632	+$28,986,682	$7,029,222	$39,617,046	$18.66	171
2022 Q4	74,882,455	$1,199,512,447	+$34,809,045	$3,066,228	$31,551,390	$16.02	143
2022 Q3	73,058,455	$950,485,507	+$31,367,178	$2,912,000	$26,798,350	$13.01	146
2022 Q2	70,661,940	$746,891,350	+$29,354,270	$2,367,000	$20,989,000	$10.56	145
2022 Q1	67,898,538	$816,547,036	+$18,128,716	$2,524,000	$3,552,000	$12.02	150
2021 Q4	66,279,662	$934,552,606	+$30,528,224	$3,964,000	$4,280,000	$14.10	157
2021 Q3	64,052,510	$654,426,634	-$173,048,089	$4,431,000	$3,664,000	$10.22	156
2021 Q2	67,744,971	$1,804,059,935	-$97,241,940	$52,400,959	$68,083,281	$26.63	170
2021 Q1	71,176,129	$2,470,272,742	-$31,512,282	$29,219,000	$6,921,000	$34.71	190
2020 Q4	71,979,588	$2,669,848,746	+$83,550,338	$25,062,000	$42,516,000	$37.09	202
2020 Q3	68,946,106	$2,836,067,721	+$69,119,809	$21,484,000	$16,338,000	$41.12	205
2020 Q2	67,276,990	$2,726,519,660	+$109,940,747	$17,528,000	$17,004,000	$40.53	188
2020 Q1	64,502,523	$2,241,446,114	+$113,121,712	$16,707,000	$10,324,000	$34.75	183
2019 Q4	61,421,765	$2,634,618,707	+$38,703,669	$21,534,000	$34,148,000	$42.89	208
2019 Q3	60,775,042	$2,247,652,301	-$21,551,953	$14,545,000	$28,722,000	$36.98	207